20.07.2017 • NewsDede WillamsPipelinerefinery

Commission Clears Ineos-BP Pipeline Deal

(c) James Jones Jr/Shutterstock
(c) James Jones Jr/Shutterstock

The European Commission has approved Ineos’ acquisition of  BP’s North Sea pipelines for   up to $250 million. The deal includes the Forties Pipeline System (FPS) that links 85 oil and gas assets to the UK mainland and to the Kinneil terminal in Grangemouth, Scotland, which is adjacent to the Ineos refinery and chemical complex.

Terms of the deal include an initial cash payment of $125 million and a seven-year earn-out arrangement potentially worth another $125 million. About 300 BP staff supporting the operations are to transfer to Ineos.

Altogether, the pipeline has capacity to transport 575,000 bbl/d of oil from the UK’s first major offshore oil field – built by BP and opened in 1975 – to the UK mainland. Around 20% of the throughput goes to feed Ineos’ Grangemouth refinery.

Ineos will own and operate the Kinneil terminal, a gas processing plant, the Dalmeny terminal, various sites in Aberdeen, Scotland, and the Forties Unity Platform, along with other associated infrastructure.

According to the Commission, the proposed acquisition would raise no competition concerns because of its limited competitive impact on the market.

“The North Sea continues to present new opportunities for Ineos,” its chairman, Jim Ratcliffe, said. He said the pipeline system is “a UK strategic asset that was originally designed to work together to feed the Grangemouth refinery and petrochemical facilities.”

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.